The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.
MEN with suspected prostate cancer will be able to get a diagnosis on the NHS within a day, under “game-changing” new trials.
The SSM Health Fond du Lac Regional Clinic is welcoming Claire Carlton, APNP-CNP, to its Urology team at 420 E. Division ...
The global Incontinence Care Products Market is on a steady growth path — estimated at USD 13.5 billion in 2025 and forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback